Právní předpis byl sestaven k datu 19.09.2014.
Zobrazené znění právního předpisu je účinné od 20.12.2013 do 19.09.2014.
98
XXXXXXX
Xxxxxxxxxxxx xxxxxxxxxxxx věcí,
xxxxxx se xxxx x doplňuje sdělení Xxxxxxxxxxxx xxxxxxxxxxxx xxxx x. 58/2007 Xx. x. x. a x. 46/2008 Xx. x. x. a xxxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx věcí x. 97/2012 Sb. x. x. x Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx sportu
Xxxxxxxxxxxx xxxxxxxxxxxx xxxx xxxxxxx, xx xxx 12. listopadu 2012 xxxx xxxxxxxxx xxxxxxxxxx XXXXXX oznámeno xxxxxxxxx xxxxxx xxxxx Přílohy X - Xxxxxxx xxxxxxxxxx xxxxx a xxxxx - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx xxxxxx xxxxx dopingu xx xxxxxx1).
S xxxxx xxxxxx Přílohy I xxxxxxxx xxxxxxx Xxxxxxxxx Xxxxx xxxxxxxxx.
Xxxx xxxxx Přílohy X xxxxxxxxx x xxxxxxxx x souladu s xxxxxxx 34 odst. 3 Xxxxxx dne 1. xxxxx 2013 x xxxxx xxxx xxxxxxxxx x xxxxxxxx x xxx Xxxxxx xxxxxxxxx. Dnem xxxxxx xxxxxx xxxxx Xxxxxxx X x platnost xxxxxxxx xxxxxx znění Xxxxxxx X Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx sportu xxxxxx xx 1. xxxxx 2012 x vyhlášené xxx č. 97/2012 Sb. m. s.
Xxxxxxxx xxxxx Xxxxxxx I x její xxxxxxx xx xxxxxxx xxxxxx xx xxxxxxxxx současně.
1) Mezinárodní xxxxxx xxxxx xxxxxxx xx xxxxxx přijatá xxx 19. xxxxx 2005 x Paříži xxxx xxxxxxxxx xxx č. 58/2007 Sb. m. s. a č. 46/2008 Sb. m. s.
XXXXXXX X
XXXXXX XXXXXXXXXX LÁTEK X METOD XXXXXXX XXX ROK 2013
XXXXXXX XXXXXXXXXXXXX XXXXX
Xxxxxx xx 1. xxxxx 2013
Xxxxx xxxxxx 4.2.2 Světového xxxxxxxxxxxxxxx kodexu xxxxxxx Xxxxxxxx látky xxxxx xxxxxxxxxx za "Xxxxxxxxxx xxxxx" xxxxx látek xx skupin X1, X2, X4.4, X4.5 x S6(a) x Xxxxxxxxxx xxxxx X1, X2 x M3.
|
LÁTKY X XXXXXX XXXXXXXX XXXXX
(PŘI SOUTĚŽI X XXXX SOUTĚŽ)
|
XXXXXXXX XXXXX
X0. XXXXXXXXXXX LÁTKY
Xxxxxxxxx xxxxxxxxxxxxx xxxxx, xxxxx xxxx zahrnuta x xxxxxxxxxxxxx sekcích Xxxxxxx x xxxx xxxxxxxx xxxxxxxxx xxx xxxxxxx xxxxxxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxx zdravotnickým regulačním xxxxxx (xxxx. xxxxxx x preklinickém xxxx xxxxxxxxx xxxxxx xxxxxxx xxxx xx ukončené xxxxxxxxxx, xxxxxxxxxx xxxxx, xxxxxxxxxxx léky), xx xxxxxxxx stále.
X1. XXXXXXXXXX XXXXX
Xxxxxxxxxx xxxxx xxxx xxxxxxxx.
1. XXXXXXXXXX ANABOLICKÉ XXXXXXXX (AAS):
(x) Xxxxxxxx* XXX, xxxxxxxxxx:
1-xxxxxxxxxxxxx (5α-androst-1-en-3β,17β-diol); 1-androstendion (5α-xxxxxxx-1-xx-3,17-xxxx); xxxxxxxxx (estr-4-en-3β,17β-diol); xxxxxxxxxx; boldenon; xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx); xxxxxxx (17α-ethynyl-17β-hydroxyandrost-4-eno[2,3-d]isoxazol); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-chloro-17β-hydroxy-17α-methylandrosta-1,4-dien-3-on); xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17β-xx); drostanolon; xxxxxxxxxxxxx (19-xxx-17α-xxxxx-4-xx-17-xx); xxxxxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxx (17β-hydroxy-17α-methyl-5α-androstano[2,3-c]-furazan); xxxxxxxxx; 4-xxxxxxxxxxxxxxxxxx (4,17β-xxxxxxxxxxxxxxxx-4-xx-3-xx); xxxxxxxxxx; xxxxxxxxx; mestanolon; xxxxxxxxxx; xxxxxxxxxxx (17β-hydroxy-17α-methylandrosta-1,4-dien-3-on); metenolon; xxxxxxxxxxx; metasteron (2α, 17α-xxxxxxxx-5α-xxxxxxxxx-3-xx-17β-xx); methyldienolon (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx); xxxxxx-1-xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx); methyltestosteron; xxxxxxxxxx (xxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx); miboleron; xxxxxxxxx; 19-norandrostendion (xxxx-4-xx-3,17-xxxx); xxxxxxxxxx; xxxxxxxxxxxxxx; norklostebol; xxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-xxxxxxx-5α-xxxxxxxxxx [3,2-x]xxxxxxx); xxxxxxxxx; stanozolol; xxxxxxxxx; 1-xxxxxxxxxxx (17β-hydroxy-5α-androst-1-en-3-on); xxxxxxxxxxxxxxxxxxx (18α-homo-pregna-4,9,11-trien-17β-ol-3-on); trenbolon x další xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
(x) Xxxxxxxxx** AAS, xxxxx xxxx xxxxxx exogenně:
Xxxxxxxxxxxxx (xxxxxxx-5-xx-3β,17β-xxxx), xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx), xxxxxxxxxxxxxxxxxx, xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, XXXX, 3ß-xxxxxxxxxxxxxx-5-xx-17-xxx), xxxxxxxxxxx x xxxxxx xxxxxxxxxx a xxxxxxx, xxx ne x xxxxxxxx xxxxx xx xx:
| &xxxx;
5α-xxxxxxxxx-3α,17α-xxxx
|
&xxxx;
5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx)
|
| &xxxx;
5α-xxxxxxxxx-3α,17β-xxxx
|
&xxxx; |
| &xxxx;
5α-xxxxxxxxx-3β,17α-xxxx
|
&xxxx;
xxx-xxxxxxxxxxxxxxxxxx
|
| &xxxx;
5α-xxxxxxxxx-3β,17β-xxxx
|
&xxxx;
xxxxxxxxxxxxxx
|
| &xxxx;
xxxxxxx-4-xx-3α,17α-xxxx
|
&xxxx;
3α-xxxxxxx-5αxxxxxxxxx-17-xx
|
| &xxxx;
xxxxxxx-4-xx-3α,17β-xxxx
|
&xxxx;
3β-xxxxxxx-5αxxxxxxxxx-17-xx
|
| &xxxx;
xxxxxxx-5-xx-3β,17α-xxxx
|
&xxxx;
7α-xxxxxxx-XXXX
|
| &xxxx;
xxxxxxx-5-xx-3α,17α-xxxx
|
&xxxx;
7β-xxxxxxx-XXXX
|
| &xxxx;
xxxxxxx-5-xx-3α,17β-xxxX
|
&xxxx;
7-xxxx-XXXX
|
| &xxxx;
xxxxxxx-5-xx-3β,17α-xxxx
|
&xxxx;
19-xxxxxxxxxxxxxx
|
| &xxxx;
4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3β,17β-xxxx)
|
&xxxx;
19-xxxxxxxxxxxxxxxxx
|
2. Xxxxxxx xxxxxxxxxx xxxxx, zahrnující:
Xxxxxxxxxxx, xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (SARM), tibolon, xxxxxxx, xxxxxxxxxx, ale xx x xxxxxxxx xxxxx xx xx.
| &xxxx;
Xxx xxxxx skupiny xxxx xxxxx: * "xxxxxxxx" xx xxxxxxxx k xxxxx, xxxxxx xxxx xxxx xxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxxxx. ** "xxxxxxxxx " xx xxxxxxxx x xxxxx, xxxxxx xxxx xxxx xxxxxxxxxx xxxxxxxxx.
|
X2. XXXXXXXXX XXXXXXX, XXXXXXX XXXXXXX A XXXXXXXX LÁTKY
Xxxxxxxxxxx xxxxx a xxxxxx xxxxxxxxxx faktory jsou xxxxxxxx:
1. Xxxxx xxxxxxxxxxx erytropoesu (např. xxxxxxxxxxxx (XXX), xxxxxxxxxxx (xXXX), stabilizátory hypoxii xxxxxxxxxxxxxx faktoru (XXX), xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx beta (CERA), xxxxxxxxxxx /Xxxxxxxx/);
2. Xxxxxxxxxxxxxxxxxx (XX) a Xxxxxxxxxxxx hormon (LH) x mužů;
3. Xxxxxxxxxxxxxx;
4. Xxxxxxx xxxxxx (XX), fibroblastové xxxxxxx xxxxxxx (XXXx), xxxxxxxxxxxx xxxxxxx xxxxxx (XXX), insulinu podobný xxxxxxx xxxxxx-1 (IGF-1), xxxxxxxxxx xxxxxxx xxxxxxx (XXX), xxxxxxx xxxxxx xxxxxxxx z xxxxxxxx xxxxxxxx (PDGF) x xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (XXXX), xxxxxx jako xxxxxxxxx xxxx xxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxx xxxx xxxxxxxxx xxxxxxxx xxxxx, xxxxx a xxxxxx, krevní xxxxxxxx, xxxxxxx energie, xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx xxxx xxxxxxxxx xxxxxx;
x xxxxx látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
S3. XXXX2- XXXXXXXX
Xxxxxxx xxxx-2 xxxxxxxx xxxxxx xxxx případných xxxxxxxxx xxxxxxx (např. x- x x-), jsou xxxxxxxx xxxxx xxxxxxxxxxx (xxxxxxxxx 1600 xxxxxxxxxx xx 24 hodin), xxxxxxxxxxx (xxxxxxxxx 36 xxxxxxxxxx za 24 xxxxx) x xxxxxxxxxxx xxxxx jsou xxxxxx x inhalaci x xxxxxxx x doporučeným xxxxxxxx režimem xxxxxxx.
Xxxxxxxxxx salbutamolu v xxxx x xxxxxxxxxxx xxxxx xxx 1000 xx/xx x přítomnost xxxxxxxxxxx x xxxx x xxxxxxxxxxx xxxxx xxx 40 xx/xx xxxxxx xxxxxxxxxx xx xxxxxxxxx terapeutické xxxxxxx, xxx xxxx považována xx pozitivní laboratorní xxxxx, xxxxx sportovec xxxxxxxxx kontrolovanou farmakokinetickou xxxxxx, xx xxxxxxxxxx xxxxxxxx byl xxxxxxxx xxxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxx xxxxx než xxxx uvedené xxxxxxx.
X4. XXXXXXXXX X XXXXXXXXXXX MODULÁTORY
Zakázané xx xxxxxxxxxxx:
1. Xxxxxxxxxx xxxxxxxx, xxxxxxxxxx:
Xxxxxxxxxxxxxxxx, anastrozol, xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (xxxxxxxxxxxxxxxxx), 4-androsten-3,6,17-trion (6-xxx),xxxxxxxxx, xxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxx xx x xxxxxxxx xxxxx na xx.
2. Xxxxxxxxxx xxxxxxxxxx estrogenových xxxxxxxxx (XXXX), xxxxxxxxxx:
Raloxifen, xxxxxxxxx, toremifen, xxx xx s omezením xxxxx xx ně.
3. Xxxxxxx xxxxxxxxxxxxxx xxxxx zahrnující:
Xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, ale xx s xxxxxxxx xxxxx xx ně.
4. Xxxxx modifikující xxxxxx myostatinu xxxxxx xxxxxxxxxx myostatinu, ale xx x xxxxxxxx xxxxx na ně.
5. Metabolické xxxxxxxxxx:
x) Insuliny;
b) Xxxxxxxx xxxxx aktivovaný xxxxxxxxxxxxxx xxxxxxxxxxxxx /Peroxisome Xxxxxxxxxxxx Xxxxxxxxx Xxxxxxxx δ (XXXXδ) agonists/ (xxxx. XX 1516) x Agonisté xxxxxxxxxxxxxxx xxx xxxxxxxxxx AMP x xxxxxxxxxxx s XXXX xxxxx /XXXXδ-XXX-xxxxxxxxx xxxxxxx xxxxxx (XXXX) xxxx xxxxxxxx/ (xxxx. XXXXX)
S5. DIURETIKA X OSTATNÍ XXXXXXXXX XXXXX
Xxxxxxxxx xxxxx xxxx zakázané. Xxxxxxxx:
Xxxxxxxxx, desmopressin, xxxxxxxxxxxxxxx (xxxx. xxxxxxxx, nitrožilní xxxxxx xxxxxxxx, dextranu, xxxxxxxxxxxxxxxxxx a xxxxxxxxx), xxxxxxxxxx a xxxxx xxxxx s podobnými xxxxxxxxxxxx účinky. Xxxxxxx xxxxxx xxxxxxxxxxxx xxx xxxxx anestézi xxxx xxxxxxxx.
Diuretika xxxxxxxx:
Xxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxx, xxxxxxxx, xxxxxxxx xxxxxxxxxx, xxxxxxxxx, spironolakton, thiazidy (xxxx. xxxxxxxxxxxxxxxxxx, hydrochlorothiazid, xxxxxxxxxxxxx), xxxxxxxxxx x xxxxx xxxxx x xxxxxxxx xxxxxxxxx strukturou xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx (xxxxx xxxxxxxxxxxx, xxxxxxxxx a lokálního xxxxxx dorzolamidu x xxxxxxxxxxxx, xxxxx nejsou xxxxxxxx).
Xxx xxxxxxx (Xxx Xxxxxxx, případně Xxxx Xxxxxx) xxxxxxxxxxx xxxxxxxx xxxxx xx xxxxxxxxxx xxxxxxxx xxxxxxx (xx. xxxxxxxxxx, xxxxxxxxxx, xxxxxx, katin, efedrin, xxxxxxxxxxxx a pseudoefedrin) xx spojení x xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxxx je xxxxxxxxxx xxxxxxx xxxxxxxxxx Xxxxxxxxxxxx xxxxxxx xx xxxx xxxxx navíc x xx, která xxx xxxx xxxxxxx xx xxxxxxxxxx xxxx xxxxx xxxxxxxxx látku.
ZAKÁZANÉ XXXXXX
X1. MANIPULACE X XXXX X XXXXXXXX KOMPONENTAMI
Zakázané xx následující:
1. Xxxxxx xxxx xxxxxxxxxxxxx xxxxxxxxx, homologní xxxx xxxxxxxxxxx xxxx nebo xxxxxxxxx xxxxxxx x xxx xxxxxxxxx xxxxxxxx xxxxxxxxxxx původu xx xxxxxxxxx xxxxxxx.
2. Xxxxx zvyšování xxxxxxxx, xxxxxxx nebo xxxxxxx xxxxxxx, zahrnující modifikované xxxxxxxxxxxxx xxxxxxxx (xxxx.xxxxxx xxxxxxxx xxxxxxxx xx xxxxxxxxxxx, mikroenkapsulované xxxxxxxxxxx), xxxxxxxxxxxxxxxxxxx x efaproxiral (XXX13), xxx xx x xxxxxxxx xxxxx xx ně. Xxxxxxxxxxxx xxxxxxxx xxxxxxxx xxxx.
3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxxxxxxx x xxxx nebo x xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxxxx xxxxxxx.
X2. XXXXXXXX A XXXXXXXXX MANIPULACE
Xxxxxxxx xx xxxxxxxxxxx:
1. Xxxxxxxxx, xxxx xxxxx x xxxxxx, xx xxxxxx xxxxxxx xxxxxxxxx x platnost Vzorků xxxxxxxxxx při Dopingové xxxxxxxx xx xxxxxxxx. Xx xxxxxxxx xxxxxx x/xxxx úpravu (např. xxxxxxxxxx) xxxx, xxx xx x xxxxxxxx xxxxx na ně.
2. Xxxxxxxxxx infuze x/xxxx xxxxxxx xxxx xxx 50 xx xx 6 xxxxx xxxx xxxxxxxx xxxxx xxxxxx legitimně xxxxxxxxx x xxxxxxx xxxxxxxxxxxx xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxx.
X3. XXXXXX XXXXXX
X xxxxxx xxxxxxxxxx xx xxxxxxx xxxxxxxxxxx výkonu xx xxxxxxxx xxxxxxxxxxx:
1. Transfer nukleových xxxxxxx xxxx xxxxxx xxxxxxxx;
2. Použití xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx;
| &xxxx;
LÁTKY X XXXXXX ZAKÁZANÉ XXX XXXXXXX
|
Xxxxx kategorií S0 xx X5 x X1 xx X3 xxxxxxxxx xxxx xxxx Xxx Xxxxxxx xxxxxxxx x xxxxxxxxxxx skupiny:
XXXXXXXX LÁTKY
X6. XXXXXXXXXXX
Všechna xxxxxxxxxxx xxxxxx xxxxx jejich xxxxxxxxxx xxxxxxxxx xxxxxxx (xxxx. x- x x-) xxxx zakázaná, x výjimkou xxxxxxxx xxxxxxxxx x případě xxxxxx xxxxxxxx xxxxxxx x stimulancií xxxxxxxxxx xx Monitorovacího xxxxxxxx xxx xxx 2013*.
Xxxxxxxxxxx xxxxxxxx:
(x) Xxxxxxxxxxxx xxxxxxxxxxx:
Xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, amfetamin, xxxxxxxxxx, benfluorex, benzfetamin, xxxxxxxxxxxxxxx, bromantan, dimethylamfetamin, xxxxxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, 4-xxxxxxxxxxxxxx (xxxxxxxx), xxxxxxxxxx, xxxxxxxxxxx, kokain, kropropamid, xxxxxxxxxx, mefenorex, mefentermin, xxxxxxxxxxxx (d-), xxxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxx, x-xxxxxxxxxxxxxxx, prenylamin, xxxxxxxxx.
Stimulancium, které xxxx výslovně xxxxxxx x xxxxx xxxxxxxx, xx Xxxxxxxxxxx xxxxxx.
(x) Specifická xxxxxxxxxxx (xxxxxxxx):
Adrenalin**, xxxxx***, xxxxxxx****, xxxxxxxx, etilefrin, xxxxxxxxxxx, xxxxxxxxxxx, fenprometamin, xxxxxxxxxx, xxxxxxxxxxxx, levmetamfetamin, xxxxxxxxxxxx, metylefedrin****, xxxxxxxxxxxxx, xxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxx), xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, oxilofrin, xxxxxxxxxxxxxxxxxxxx, xxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxxxx*****xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx x xxxxx látky s xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
* Následující xxxxx zahrnuté xx Xxxxxxxxxxxxxx xxxxxxxx 2013 (xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, nikotin, xxxxxxxxx, xxxxxxxx) xxxxxx xxxxxxxxxx xx Zakázané xxxxx.
** Lokální xxxxxx xxxxxxxxxx (xxxx. nosní, xxxx xxxxxxxx) xxxx xxxx podání xxxxxxxx x xxxxxxxxx xxxxxxxxxx xxxx zakázáno.
*** Xxxxx xx zakázaný xxxxx xxx xxxxxxxxxxx xxxxx xxx 5 xxxxxxxxxx v 1 xx xxxx.
**** Xxxxxxx x methylefedrin xxxx xxxxxxxx xxx xxxxxxxxxxx vyšší než 10 xxxxxxxxxx v 1 ml xxxx.
***** Pseudoefedrin xx xxxxxxx, pokud xxxx xxxxxxxxxxx x moči xx xxxxx než 150 xxxxxxxxxx xx xxxxxxxx
S7. XXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
Xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx(xxxxxx), xxxxxxxx x xxxx xxxxxxxx, xxxxxxxxxxx, metadon, xxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxx.
X8. XXXXXXXXXXX
Xxxxxxxx (např. xxxxx, xxxxxx a xxxxxxxxx) xxxx xxxxxxxxxx xxxxx9-xxxxxxxxxxxxxxxxxxx (XXX) x xxxxxxxxxxxxxx (xxxx. "Xxxxx" /XXX018, JWH073/ x XX-210) xxxx zakázané.
X9. XXXXXXXXXXXXXXXXXXXX
Xxxxxxx xxxxxxxxxxxxxxxxxxxx xxxxxxxx xxxxxx, xxxxxxxx, xxxxxxxxxx xxxx xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxx.
| &xxxx;
XXXXX XXXXXXXX X XXXXXXXX SPORTECH
|
P1. ALKOHOL
Xxxxxxx (etanol) xx xxxxxxxx xxxxx Xxx Xxxxxxx x xxxxxxxxxxxxx xxxxxxxx. Detekce xx xxxx provádět xxxxxxxx xxxxxxxx x/xxxx rozborem xxxx. Xxxxxxx hodnota xxx xxxxxxxx xxxxxxxxxxx xxxxxxxx (xxxxxxxxxxxxx hodnota) xx 0.10 x/x.
∙ Automobilový xxxxx (XXX)
∙ Karate (XXX)
∙ Xxxxxxx xxxxxx a xxxxxxxxxxxx(XXX)
∙ Xxxxxxxxxxx (XXXX)
∙ Xxxxxxxxxxx xxxxx (XXX)
∙ Vodní xxxxxxxxxx (XXX)
X2. XXXX-XXXXXXXXX
Xxxxx xxxx xxxxx xxxxxx, beta-blokátory xxxx zakázány xxxxx Xxx Xxxxxxx x xxxxxxxxxxxxx xxxxxxxx.
∙ Xxxxxxxxxxxx xxxxx (XXX)
∙ Billiard (xxxxxxx xxxxxxxxxx) (WCBS)
∙ Xxxx (IGF)
∙ Xxxxxxxxxxx (XXXX, XXX) (xxxxxxxx xxxx Xxxx xxxxxx)
∙ Lyžování (XXX) - xxxxx xx xxxxxx x xxxxxxxxxxx xxxxxxxx-xxxxx a X-xxxxx,x xxxxxxxxx U-rampa x "big air"
∙ Střelba (ISSF, XXX) (xxxxxxxx xxxx Xxxx soutěž)
∙ Xxxxx (WDF)
Beta-blokátory xxxxxxxx xxxxxxxxxxx xxxxx:
Xxxxxxxxxx, xxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, esmolol, xxxxxxxxx, xxxxxxxxxx, labetalol, xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, pindolol, propranolol, xxxxxxx, xxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx.
Xxxxxxxxx
Xxxxxx předpis č. 98/2013 Xx. x. x. xxxxx xxxxxxxxx xxxx 20.12.2013.
Právní xxxxxxx x. 98/2013 Xx. m. x. xxx xxxxxx xxxxxxx xxxxxxxxx č. 47/2014 Sb. m. s. x xxxxxxxxx od 20.9.2014.
Znění xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx xxxxxxxx předpisů x xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx xx jich xxxxxx xxxxxxxxx změna xxxxx uvedeného xxxxxxxx xxxxxxxx.